[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100054080":3},{"organization":4,"outcomesModule":7,"designInfo":33,"detailedDescription":36,"studyPopulation":37,"armGroups":32,"interventions":38,"overallOfficials":43,"centralContacts":60,"locations":66,"responsibleParty":77,"collaborators":79,"id":83,"slug":84,"hasResults":85,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":85,"sex":91,"minAge":92,"maxAge":32,"enrollmentInfo":93,"targetDuration":96,"studyType":97,"phases":32,"briefSummary":98,"conditions":99,"keywords":32,"overallStatus":69,"whyStopped":32,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},{"fullName":5,"class":6},"iOMEDICO AG","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":32},[9],{"measure":10,"description":11,"timeFrame":12},"Course of treatment (treatment reality)","Documentation of anamnestic data and therapy sequences","5 years per patient",[14,17,20,23,26,29],{"measure":15,"description":16,"timeFrame":12},"Best Response","Documentation of response rates per line of treatment.",{"measure":18,"description":19,"timeFrame":12},"Progression-free survival","Documentation of progression-free survival per line of treatment.",{"measure":21,"description":22,"timeFrame":12},"Overall survival","Documentation of overall survival time.",{"measure":24,"description":25,"timeFrame":12},"Health-related quality of life (Patient-reported outcome)","EORTC QLQ-C30 core questionnaire.",{"measure":27,"description":28,"timeFrame":12},"Myeloma-specific health-related quality of life (Patient-reported outcome)","EORTC QLQ-MY20, the myeloma specific module.",{"measure":30,"description":31,"timeFrame":12},"Quality of life (Patient-reported outcome)","Brief Pain Inventory (BPI)",null,{"allocation":32,"interventionModel":32,"interventionModelDescription":32,"primaryPurpose":32,"observationalModel":34,"timePerspective":35,"maskingInfo":32},"COHORT","PROSPECTIVE","MYRIAM is a national, observational, prospective, longitudinal, multicenter cohort study (tumor registry platform) with the purpose to record information on the antineoplastic treatment of multiple myeloma in Germany. The registry will follow patients for up to five years. It will identify common therapeutic sequences and changes in the treatment of the disease. At inclusion, data in patient characteristics, comorbidities, tumor characteristics and previous treatments are collected. During the course of observation data on all systemic treatments, radiotherapies, surgeries, and outcome are documented.\n\nHealth-realted quality of life in patients with multiple myeloma (MyLife) will be evaluated for up to five years.","Adult patients with multiple myeloma (MM) requiring systemic treatment",[39],{"type":40,"name":41,"description":42,"armGroupLabels":32,"otherNames":32},"OTHER","Routine care as per site standard.","Physician's choice according to patient's needs.",[44,48,51,54,57],{"name":45,"affiliation":46,"role":47},"Hermann Einsele, Prof MD","Wuerzburg University Hospital","STUDY_CHAIR",{"name":49,"affiliation":50,"role":47},"Monika Engelhardt, Prof MD","Universitätsklinikum Freiburg",{"name":52,"affiliation":53,"role":47},"Tobias Dechow, Prof MD","Onkologie Ravensburg",{"name":55,"affiliation":56,"role":47},"Wolfgang Knauf, Prof MD","Centrum für Hämatologie und Onkologie Bethanien",{"name":58,"affiliation":59,"role":47},"Norbert Marschner, MD","Praxis für interdisziplinäre Onkologie & Hämatologie",[61],{"name":62,"role":63,"phone":64,"phoneExt":32,"email":65},"Martina Jänicke, PhD","CONTACT","+49 761 15242-0","info@iomedico.de",[67],{"facility":68,"status":69,"city":70,"state":32,"zip":32,"country":71,"countryCode":72,"cosmosGeoPoint":32,"geoPoint":32,"contacts":73},"Multiple sites all over germany","RECRUITING","Multiple Sites","Germany","DE",[74],{"name":5,"role":63,"phone":75,"phoneExt":32,"email":76},"+49 761 152420","info@iomedico.com",{"type":78,"investigatorFullName":32,"investigatorTitle":32,"investigatorAffiliation":32,"oldNameTitle":32,"oldOrganization":32},"SPONSOR",[80],{"name":81,"class":82},"Deutsche Studiengruppe Multiples Myelom (DSMM)","UNKNOWN","100054080","myeloma-registry-platform-myriam-100054080",false,"NCT03308474","Myeloma Registry Platform (MYRIAM)","Clinical Research Platform for Molecular Testing, Treatment and Outcome of Patients With Multiple Myeloma (Myeloma Registry Platform; MYRIAM)","MYRIAM","Inclusion Criteria:\n\n* MM requiring systemic (first-, second- or third-line) treatment (closed for first-line \u002F second-line recruitment)\n* Age ≥ 18 years\n* Written informed consent\n\n  * Patients participating in the PRO satellite: signing of informed consent and completion of baseline questionnaire before, but not more than eight weeks before the start of respective systemic treatment\n  * Patients not participating in the PRO satellite: signing of informed consent not later than four weeks after start of respective treatment, and not more than eight weeks before the start of respective systemic treatment\n* Sufficient German language skills for participation in the PRO satellite\n\nExclusion Criteria:\n\n* No systemic therapy for myeloma\n* Patients already enrolled in studies that prohibit any participation in other studies","ALL","18 Years",{"count":94,"type":95},2200,"ESTIMATED","5 Years","OBSERVATIONAL","The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study with associated satellites, a tumor registry platform, to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with Multiple Myeloma in Germany.",[100],"Multiple Myeloma","2026-07-10",{"date":103,"type":104},"2026-07-13","ACTUAL",{"date":106,"type":104},"2017-09-25",{"date":108,"type":95},"2028-12",{"name":5,"class":6},1]